glutathione inhibitor iFSP1 is a Selective FSP1 Glutathione-Independently JKE-1674

Studies have found that this peptide encourages greater gut health, tissue regene

Patients with impaired kidney function may require dose adjustments or may not be suitable candidates for Alimta, as the drug is primarily eliminated through the kidneys

Nutrition Bytes

In contrast, the hard-template method, also referred to as nano-casting, uses pre-designed solid templates with mesoporous structures

Contacts for further information Media: Ambre James-Brown +45 3079 9289 [email protected] Liz Skrbkova (US) +1 609 917 0632 [email protected] Data presented simultaneously at the American Diabetes Association's 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of 5%, 20%, 25%, and 30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 Bagsvrd, Denmark, 22 June - Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM